TY - JOUR
T1 - Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau
AU - Tanemura, Kentaro
AU - Akagi, Takumi
AU - Murayama, Miyuki
AU - Kikuchi, Naomi
AU - Murayama, Ohoshi
AU - Hashikawa, Tsutomu
AU - Yoshiike, Yuji
AU - Park, Jung Mi
AU - Matsuda, Keiko
AU - Nakao, Shinobu
AU - Sun, Xiaoyan
AU - Sato, Shinji
AU - Yamaguchi, Haruyasu
AU - Takashima, Akihiko
N1 - Funding Information:
We thank T. Miyakawa (Kumamoto Univ.) for helpful suggestions, J. Kobayashi for manuscript preparation, and C. L. Dolorfo for manuscript editing (Exact Science Communications). This work is partly supported by CREST (Japan Science and Technology, JST), Grant-in-Aid for Scientific Research on Priority Areas (the Japanese Ministry of Education, Science and Culture), and a grant-in-aid for Scientific Research (11680746, the Japanese Ministry of Education, Science and Culture).
PY - 2001
Y1 - 2001
N2 - Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.
AB - Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.
UR - http://www.scopus.com/inward/record.url?scp=0035664048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035664048&partnerID=8YFLogxK
U2 - 10.1006/nbdi.2001.0439
DO - 10.1006/nbdi.2001.0439
M3 - Article
C2 - 11741399
AN - SCOPUS:0035664048
SN - 0969-9961
VL - 8
SP - 1036
EP - 1045
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 6
ER -
